• To characterize hepatitis C virus (HCV) epidemiology and inform public health research, policy, and programming priorities in Afghanistan.
RESULTS
• Our search identified 1 HCV incidence and 69 HCV prevalence measures (Figure 1 ).
• HCV incidence was only assessed among people who inject drugs (PWID), and was reported at 66.7 per 100 person-years.
• Our meta-analyses estimated HCV prevalence at (Table 1) :
• 0.6% among the general population (range: 0-9.1%; 95% CI: 0.3-0.9%)
• 32.6% among PWID (range: 9.5-70.0%; 95% CI: 24.5-41.3%)
• 2.3% among populations at intermediate risk such as prisoners (range: 0.0-8.3%; 95% CI: 1.3-3.7%) • No data was available for clinical populations at high risk such as hemodialysis, thalassemia, and hemophilia patients.
• HCV measures were of reasonable quality.
BACKGROUND
• There is potential for achieving substantial reductions in HCV transmission due to recent innovations in HCV treatment and prevention.
• HCV epidemiology in most countries in the Middle East and North Africa (MENA) including Afghanistan is poorly understood.
• Afghanistan may be vulnerable to the transmission of blood-borne infections including HCV due to decades of armed conflicts and opium cultivation and trade.
• This study is part of the MENA HCV Epidemiology Synthesis Project; an ongoing effort to characterize HCV epidemiology and inform key public health research, policy, and programming priorities in MENA.
METHODOLOGY
• We systematically reviewed and synthesized HCV incidence and prevalence data using a comprehensive search of literature and following PRISMA guidelines (Figure 1 ).
• HCV prevalence among various at risk populations were estimated through meta-analyses implemented using DerSimonian-Laird random effects models with inverse variance weighting (Table 1) .
• Heterogeneity across studies was assessed using several measures (Table 1 ).
• A detailed assessment for the quality of HCV measures (risk of bias and precision) was conducted. 
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